Objectives
In the Fluid and Catheter Treatment Trial (FACTT) of the National
Institutes of Health Acute Respiratory Distress Syndrome Network, a
conservative fluid protocol (FACTT Conservative) resulted in a lower
cumulative fluid balance and better outcomes than a liberal fluid protocol
(FACTT Liberal). Subsequent Acute Respiratory Distress Syndrome Network
studies used a simplified conservative fluid protocol (FACTT Lite). The
objective of this study was to compare the performance of FACTT Lite, FACTT
Conservative, and FACTT Liberal protocols.
Design
Retrospective comparison of FACTT Lite, FACTT Conservative, and FACTT
Liberal. Primary outcome was cumulative fluid balance over 7 days. Secondary
outcomes were 60-day adjusted mortality and ventilator-free days through day
28. Safety outcomes were prevalence of acute kidney injury and new
shock.
Setting
ICUs of Acute Respiratory Distress Syndrome Network participating
hospitals.
Patients
Five hundred three subjects managed with FACTT Conservative, 497
subjects managed with FACTT Liberal, and 1,124 subjects managed with FACTT
Lite.
Interventions
Fluid management by protocol.
Measurements and Main Results
Cumulative fluid balance was 1,918 ± 323 mL in FACTT Lite,
−136 ±491 mL in FACTT Conservative, and 6,992 ± 502
mL in FACTT Liberal (p < 0.001). Mortality was not
different between groups (24% in FACTT Lite, 25% in FACTT
Conservative and Liberal, p = 0.84).
Ventilator-free days in FACTT Lite (14.9 ±0.3) were equivalent to
FACTT Conservative (14.6±0.5) (p = 0.61)
and greater than in FACTT Liberal (12.1 ±0.5, p
< 0.001 vs Lite). Acute kidney injury prevalence was 58% in
FACTT Lite and 57% in FACTT Conservative (p
= 0.72). Prevalence of new shock in FACTT Lite (9%) was
lower than in FACTT Conservative (13%) (p =
0.007 vs Lite) and similar to FACTT Liberal (11%)
(p = 0.18 vs Lite).
Conclusions
FACTT Lite had a greater cumulative fluid balance than FACTT
Conservative but had equivalent clinical and safety outcomes. FACTT Lite is
an alternative to FACTT Conservative for fluid management in Acute
Respiratory Distress Syndrome.
The novel power-pulse spray (P-PS) technique maximizes and combines the advantages and minimizes the disadvantages of both chemical thrombolysis (CT) and rheolytic thrombectomy (RT). Forty-nine consecutive patients with iliofemoral thrombotic occlusion were treated via P-PS technique. Using a 6 Fr RT catheter, saline prime was exchanged for thrombolytic solution [group 1, 10-20 mg tenecteplase (TNK)/50 cc saline, n = 25; group 2, 1,000,000 urokinase (UK)/50 cc saline, n = 24]. The outflow port was closed, then the catheter was advanced at 1 mm increments while pulsing lytic agent. After 30-min lysis time, RT and definitive treatment of the underlying stenosis were performed. Procedure success was 23/25 (92%) and 22/24 (91.6%) for group 1 and 2, respectively. The mean total procedure time was 72 and 75 min in group 1 and 2, respectively. Thirty-day limb salvage was 91% in both groups. There were no major surgical complications. The P-PS technique is safe and effective using either UK or TNK, offering several potential advantages over monotherapy, including more rapid revascularization, decreases systemic lytic exposure and bleeding complications while facilitating both CT and RT capacity and efficacy.
Critical limb ischemia (CLI) remains a poorly understood, rarely reported, and inconsistently treated major global healthcare epidemic. The incidence in the US is estimated at 1% of the population aged 50 years and older and at approximately double that rate in the over-70 age group. These frequencies are expected to increase significantly with the aging population and the expected increase in diabetes. Within 1 year of being diagnosed with CLI, 40% to 50% of the now 20 million US diabetics will experience an amputation, and 20% to 25% will die. The estimate for treating CLI in the US alone is $10 to $20 billion per year, but just a 25% reduction in amputations could save $2.9 to $3.0 billion annually. Infrainguinal bypass surgery (IBS) utilizing autogenous saphenous vein has been considered the "24-carat gold standard" treatment for CLI, but over the last decade, endovascular therapy has emerged to seriously challenge IBS, which has created considerable controversy. Despite an overall lack of "hard" level I data, many interventionists are questioning the role of IBS as a first-line CLI therapy or are at least now considering IBS a "tainted" gold standard ("14-carat"). This review will examine the available evidence, but there should be no doubt regarding the huge global clinical and economic impact of CLI and amputations.
TRT is feasible during EVAR in high-risk patients. Further investigation is warranted to determine the safety and efficacy of TRT in preserving renal function during EVAR.
By JACEP Open policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.